Mode
Text Size
Log in / Sign up
N/A Completed N=30 Treatment

Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study

Source: ClinicalTrials.gov NCT02575911 ↗
Enrolled (actual)
30
Serious AEs
0.8%
Results posted
May 2017
Primary outcomePrimary: Flap Thickness Accuracy Within the Central Zone at Month 3 Postoperative — 125.8 micrometers

Summary

The purpose of this study is to evaluate the thickness accuracy of Laser-assisted in situ keratomileusis (LASIK) flaps created with the LenSx® Laser.

Outcome Measures

OutcomeResultp-value
PRIMARY
Flap Thickness Accuracy Within the Central Zone at Month 3 Postoperative
125.8
SECONDARY
Flap Thickness Accuracy Within the Central Zone at Month 1 Postoperative
127.8
SECONDARY
Flap Thickness Precision Within the Central Zone at Month 1 and Month 3 Postoperative
127.8; 125.8
SECONDARY
Ease of Flap Dissection at Day 0, Operative Day
4.7
SECONDARY
Stromal Bed Quality at Day 0, Operative Day
5.0
SECONDARY
Opaque Bubble Layer (OBL) at Day 0, Operative Day
0.3
SECONDARY
Uncorrected Distance Visual Acuity (UCDVA) at Month 1 and Month 3 Postoperative
0.0; 0.0; 81.0; 84.5; 8.6; 6.9
SECONDARY
Best Corrected Distance Visual Acuity (BCDVA) by Visit
0.0; 1.7; 0.0; 91.7; 91.4; 98.3
SECONDARY
Manifest Refraction Spherical Equivalent (MRSE)
-2.846; -0.194; -0.166
SECONDARY
Prediction Error Between Target Versus Achieved Refraction at One and Three Months Post-op
93.1; 91.4; 98.3; 100.0

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with myopia or hyperopia and eligible for femtosecond laser initiated LASIK surgery;
  • Best corrected visual acuity (BCVA) correctable to at least 20/25 in each eye;
  • If contact lens wearer, willing to discontinue contact lens wear prior to screening procedures;
  • Willing and able to return for ALL scheduled follow-up examinations;
  • Willing and able to provide written informed consent;
  • Eligible for bilateral LASIK procedures to be done on the same day;
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria

  • Previous corneal surgery, corneal lesions that will impede laser treatment, corneal edema, hypotony, glaucoma, existing corneal implant, or keratoconus;
  • Known sensitivity to planned study concomitant medications;
  • Participation in any other ophthalmic drug or device clinical study for 30 days prior to or during the time of participation in this study;
  • Irregular astigmatism, based on the Investigator's judgement;
  • Pregnant, lactating or planning to become pregnant during the course of the study;
  • Other protocol-specified exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02575911). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search